323 related articles for article (PubMed ID: 31216821)
1. [Influence of different timing of
He CX; Kong FT; Liang F; Wang KX; Li H; Liu YL; Zhao W; Zhou PP; Kong FL
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1731-1734. PubMed ID: 31216821
[No Abstract] [Full Text] [Related]
2. [Influence of Saccharomyces boulardii Sachets combined with bismuth quadruple therapy for initial
Zhu XY; Du J; Wu J; Zhao LW; Meng X; Liu GF
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(30):2353-2356. PubMed ID: 28822453
[No Abstract] [Full Text] [Related]
3. [Influence of two kinds of probiotics combined with bismuth quadruple therapy for
Zhu XY; Du J; Zhao WJ; Wu J; Zhao LW; Meng X; Yang L; Jiao L; Ma H
Zhonghua Yi Xue Za Zhi; 2018 Jul; 98(28):2246-2249. PubMed ID: 30078279
[No Abstract] [Full Text] [Related]
4.
Qu P; Liu X; Xia X; Xie X; Luo J; Cheng S; Chi J; Liu P; Li H; Zhao W; Yang H; Xu C
Front Cell Infect Microbiol; 2022; 12():903002. PubMed ID: 35880079
[TBL] [Abstract][Full Text] [Related]
5. [A multi-center, randomized controlled study on the effect of
Yang GB; Hu FL; Cheng W; Gao JQ; Sheng ZY; Zhang YJ; Du XL; Zuo Y; Li Y; Chen BM; Wang ZH; Zhao Z
Zhonghua Yi Xue Za Zhi; 2022 May; 102(18):1383-1388. PubMed ID: 35545584
[No Abstract] [Full Text] [Related]
6. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
7. [Jinghuaweikang capsules combined with furazolidone-based triple or quadruple therapy as the rescue treatment for Helicobacter pylori infection: a multicenter randomized controlled clinical trial].
Cheng H; Hu FL; Sheng JQ; An HJ; Xu L; Liu FX; Li Y; Hao Q; Zheng PY; Lu GF; Cao ZQ; Wang YP
Zhonghua Yi Xue Za Zhi; 2016 Nov; 96(40):3206-3212. PubMed ID: 27852385
[No Abstract] [Full Text] [Related]
8. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
Naghibzadeh N; Salmani F; Nomiri S; Tavakoli T
BMC Gastroenterol; 2022 Mar; 22(1):107. PubMed ID: 35255819
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
10.
Zhao Y; Yang Y; Aruna ; Xiao J; Song J; Huang T; Li S; Kou J; Huang L; Ji D; Xiong S; Peng W; Xu S; Cheng B
Front Med (Lausanne); 2021; 8():776955. PubMed ID: 34869495
[No Abstract] [Full Text] [Related]
11. [Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study].
Wang S; Wang W; Chu Y; Teng G; Hu F
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):576-9. PubMed ID: 24762684
[TBL] [Abstract][Full Text] [Related]
12. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
13. [A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with
Ma PP; Meng LN; Wang MT; Jin HF; Fan YH; Zha AS; Huo XH; Chen DF; Cao ZQ; Tang XF; Yang P; Shi ZH; Li TW; Meng J; Gan C; Chen GX; Sha WH; Du Q; Li Y; Lyu B
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(26):2060-2065. PubMed ID: 34275239
[No Abstract] [Full Text] [Related]
14. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Fakheri H; Bari Z; Sardarian H
Helicobacter; 2012 Aug; 17(4):264-8. PubMed ID: 22759325
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
[TBL] [Abstract][Full Text] [Related]
16. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
18. Vonoprazan on the Eradication of Helicobacter pylori Infection.
Huang J; Lin Y
Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
[TBL] [Abstract][Full Text] [Related]
19. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Cheng H; Hu FL
World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
[TBL] [Abstract][Full Text] [Related]
20. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
